Skip to main content
Fig. 5 | Alzheimer's Research & Therapy

Fig. 5

From: Enhancement of tripartite synapses as a potential therapeutic strategy for Alzheimer’s disease: a preclinical study in rTg4510 mice

Fig. 5

LDN/OSU-0215111 modifies disease progression. In a cohort of rTg4510 compound-treated mice, treatment was terminated, and 30 days later, behavioral analysis (n = 9/9/6/4, respectively), tissue collection, and LTP were performed. a Hyperactivity in the open field and b cognitive function in the NORT remained normalized in the rTg4510 treatment STOP group relative to the rTg4510 vehicle group. c PSD-95 protein expression in hippocampal postsynaptic densities of rTg4510 mice continued to remain significantly higher in the treatment STOP group compared to the vehicle group. d, e Hippocampal functional connectivity in the CA3-CA1 circuit at (n = 4/11, 4/17, 3/10, 4/14, and 2/9, respectively). d Input/output (IO) curves for all five groups of mice. All rTg4510 mice exhibit reduced synaptic strength compared to controls. However, both compound cessation and continuation groups show enhanced synaptic strength compared to rTg4510 vehicle mice. e Vehicle-treated rTg4510 mice displayed significantly reduced LTP, while the compound treatment cessation and continuation groups displayed LTP that was indistinguishable from control vehicle mice. Of note, compound-treated controls displayed significantly increased LTP relative to control vehicles. TBS, theta-burst stimulation. *P < 0.05, **P < 0.01, ***P < 0.001

Back to article page